Literature DB >> 26369984

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.

E M C Driessen1, P de Lorenzo2, M Campbell3, M Felice4, A Ferster5, I Hann6, A Vora7, L Hovi8, G Escherich9, C K Li10, G Mann11, T Leblanc12, F Locatelli13, A Biondi13, J Rubnitz14, M Schrappe15, L Silverman16, J Stary17, R Suppiah18, T Szczepanski19, M Valsecchi2, R Pieters1,20,21.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26369984     DOI： 10.1038/leu.2015.246

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia.

Authors:  D J P M Stumpel; P Schneider; L Seslija; H Osaki; O Williams; R Pieters; R W Stam
Journal:  Leukemia       Date:  2011-10-21       Impact factor: 11.528

2.  Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study.

Authors:  Georg Mann; Andishe Attarbaschi; Martin Schrappe; Paola De Lorenzo; Christina Peters; Ian Hann; Giulio De Rossi; Maria Felice; Birgitte Lausen; Thierry Leblanc; Tomasz Szczepanski; Alina Ferster; Gritta Janka-Schaub; Jeffrey Rubnitz; Lewis B Silverman; Jan Stary; Myriam Campbell; Chi Kong Li; Ram Suppiah; Andrea Biondi; Ajay Vora; Maria Grazia Valsecchi; Rob Pieters
Journal:  Blood       Date:  2010-06-30       Impact factor: 22.113

3.  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.

Authors:  Gesche Tallen; Richard Ratei; Georg Mann; Gertjan Kaspers; Felix Niggli; Alexandr Karachunsky; Wolfram Ebell; Gabriele Escherich; Martin Schrappe; Thomas Klingebiel; Ruediger Fengler; Günter Henze; Arend von Stackelberg
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

4.  Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.

Authors:  M Dördelmann; A Reiter; A Borkhardt; W D Ludwig; N Götz; S Viehmann; H Gadner; H Riehm; M Schrappe
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

5.  Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.

Authors:  J A P Spijkers-Hagelstein; S S Pinhanços; P Schneider; R Pieters; R W Stam
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

6.  Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  K Nguyen; M Devidas; S-C Cheng; M La; E A Raetz; W L Carroll; N J Winick; S P Hunger; P S Gaynon; M L Loh
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528

7.  Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation.

Authors:  Yoshiyuki Kosaka; Katsuyoshi Koh; Naoko Kinukawa; Yoshihiro Wakazono; Keiichi Isoyama; Takanori Oda; Yasuhide Hayashi; Shigeru Ohta; Hiroshi Moritake; Megumi Oda; Yoshihisa Nagatoshi; Hisato Kigasawa; Yasushi Ishida; Akira Ohara; Ryouji Hanada; Masahiro Sako; Takeyuki Sato; Shuki Mizutani; Keizo Horibe; Eiichi Ishii
Journal:  Blood       Date:  2004-08-05       Impact factor: 22.113

8.  Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group.

Authors:  Daisuke Tomizawa; Katsuyoshi Koh; Masahiro Hirayama; Takako Miyamura; Michiki Hatanaka; Yutaka Saikawa; Eiichi Ishii
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

9.  Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia.

Authors:  K Koh; D Tomizawa; A Moriya Saito; T Watanabe; T Miyamura; M Hirayama; Y Takahashi; A Ogawa; K Kato; K Sugita; T Sato; T Deguchi; Y Hayashi; J Takita; Y Takeshita; M Tsurusawa; K Horibe; S Mizutani; E Ishii
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

10.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

Authors:  Rob Pieters; Martin Schrappe; Paola De Lorenzo; Ian Hann; Giulio De Rossi; Maria Felice; Liisa Hovi; Thierry LeBlanc; Tomasz Szczepanski; Alice Ferster; Gritta Janka; Jeffrey Rubnitz; Lewis Silverman; Jan Stary; Myriam Campbell; Chi-Kong Li; Georg Mann; Ram Suppiah; Andrea Biondi; Ajay Vora; Maria Grazia Valsecchi
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321
View more
  11 in total

1.  Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL.

Authors:  Matthias Wölfl; Mareike Rasche; Matthias Eyrich; Renate Schmid; Dirk Reinhardt; Paul G Schlegel
Journal:  Blood Adv       Date:  2018-06-26

2.  Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports).

Authors:  Fiona Poyer; Anna Füreder; Wolfgang Holter; Christina Peters; Heidrun Boztug; Michael Dworzak; Gernot Engstler; Waltraud Friesenbichler; Stefan Köhrer; Roswitha Lüftinger; Leila Ronceray; Volker Witt; Herbert Pichler; Andishe Attarbaschi
Journal:  Ther Adv Hematol       Date:  2022-05-23

3.  CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.

Authors:  Holly L Pacenta; Theodore W Laetsch; Samuel John
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

Review 4.  The Prenatal Origin of Childhood Leukemia: Potential Applications for Epidemiology and Newborn Screening.

Authors:  Erin L Marcotte; Logan G Spector; Daniela P Mendes-de-Almeida; Heather H Nelson
Journal:  Front Pediatr       Date:  2021-04-23       Impact factor: 3.418

5.  Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.

Authors:  Allison Barz Leahy; Kaitlin J Devine; Yimei Li; Hongyan Liu; Regina Myers; Amanda DiNofia; Lisa Wray; Susan R Rheingold; Colleen Callahan; Diane Baniewicz; Maria Patino; Haley Newman; Stephen P Hunger; Stephan A Grupp; David M Barrett; Shannon L Maude
Journal:  Blood       Date:  2022-04-07       Impact factor: 25.476

6.  A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.

Authors:  Klaartje Somers; Victoria W Wen; Shiloh M C Middlemiss; Brenna Osborne; Helen Forgham; MoonSun Jung; Mawar Karsa; Molly Clifton; Angelika Bongers; Jixuan Gao; Chelsea Mayoh; Newsha Raoufi-Rad; Eric P Kusnadi; Kate M Hannan; David A Scott; Alan Kwek; Bing Liu; Claudia Flemming; Daria A Chudakova; Ruby Pandher; Tim W Failes; James Lim; Andrea Angeli; Andrei L Osterman; Toshihiko Imamura; Ursula R Kees; Claudiu T Supuran; Richard B Pearson; Ross D Hannan; Thomas P Davis; Joshua McCarroll; Maria Kavallaris; Nigel Turner; Andrei V Gudkov; Michelle Haber; Murray D Norris; Michelle J Henderson
Journal:  Oncogene       Date:  2019-01-22       Impact factor: 9.867

7.  Hematopoietic stem cell transplant in two pediatric patients testing positive for SARS-CoV-2: A case report.

Authors:  Jennifer Krajewski; Jing Chen; Juhi Motiani; Aryeh Baer; Burton Appel; Johannes Zakrzewski; Melanie Hankewycz; Nancy Durning; Alfred Gillio
Journal:  Pediatr Transplant       Date:  2021-10-27

Review 8.  Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia.

Authors:  Marta Malczewska; Kamil Kośmider; Kinga Bednarz; Katarzyna Ostapińska; Monika Lejman; Joanna Zawitkowska
Journal:  Cancers (Basel)       Date:  2022-04-16       Impact factor: 6.575

9.  The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.

Authors:  Marius Külp; Anna Lena Siemund; Patrizia Larghero; Alissa Dietz; Julia Alten; Gunnar Cario; Cornelia Eckert; Aurélie Caye-Eude; Hélène Cavé; Michela Bardini; Giovanni Cazzaniga; Paola De Lorenzo; Maria Grazia Valsecchi; Laura Diehl; Halvard Bonig; Claus Meyer; Rolf Marschalek
Journal:  iScience       Date:  2022-06-16

10.  Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study.

Authors:  Andre Manfred Willasch; Christina Peters; Petr Sedláček; Jean-Hugues Dalle; Vassiliki Kitra-Roussou; Akif Yesilipek; Jacek Wachowiak; Arjan Lankester; Arcangelo Prete; Amir Ali Hamidieh; Marianne Ifversen; Jochen Buechner; Gergely Kriván; Rose-Marie Hamladji; Cristina Diaz-de-Heredia; Elena Skorobogatova; Gérard Michel; Franco Locatelli; Alice Bertaina; Paul Veys; Sophie Dupont; Reuven Or; Tayfun Güngör; Olga Aleinikova; Sabina Sufliarska; Mikael Sundin; Jelena Rascon; Ain Kaare; Damir Nemet; Franca Fagioli; Thomas Erich Klingebiel; Jan Styczynski; Marc Bierings; Kálmán Nagy; Manuel Abecasis; Boris Afanasyev; Marc Ansari; Kim Vettenranta; Amal Alseraihy; Alicja Chybicka; Stephen Robinson; Yves Bertrand; Alphan Kupesiz; Ardeshir Ghavamzadeh; Antonio Campos; Herbert Pichler; Arnaud Dalissier; Myriam Labopin; Selim Corbacioglu; Adriana Balduzzi; Jacques-Emmanuel Galimard; Peter Bader
Journal:  Bone Marrow Transplant       Date:  2020-03-17       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.